Aerovate Therapeutics, Inc.
AVTE
$2.66
$0.083.10%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.54% | 25.48% | 17.72% | 17.16% | 17.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.37% | 20.03% | 38.60% | 47.66% | 52.92% |
| Operating Income | 8.37% | -20.03% | -38.60% | -47.66% | -52.92% |
| Income Before Tax | 7.81% | -20.61% | -37.04% | -43.85% | -46.57% |
| Income Tax Expenses | -1.79% | 124.00% | 124.00% | 124.00% | 124.00% |
| Earnings from Continuing Operations | 7.80% | -20.65% | -37.07% | -43.88% | -46.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.80% | -20.65% | -37.07% | -43.88% | -46.61% |
| EBIT | 8.37% | -20.03% | -38.60% | -47.66% | -52.92% |
| EBITDA | 8.61% | -19.77% | -38.61% | -47.68% | -52.93% |
| EPS Basic | 14.63% | -9.29% | -21.32% | -30.60% | -36.29% |
| Normalized Basic EPS | 14.64% | -9.24% | -21.28% | -30.56% | -36.25% |
| EPS Diluted | 14.63% | -9.29% | -21.32% | -30.60% | -36.29% |
| Normalized Diluted EPS | 14.64% | -9.24% | -21.28% | -30.56% | -36.25% |
| Average Basic Shares Outstanding | 8.31% | 10.68% | 13.01% | 10.22% | 7.55% |
| Average Diluted Shares Outstanding | 8.31% | 10.68% | 13.01% | 10.22% | 7.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
